Close Menu

Latin America

According to CNN, Brazil has announced that a SARS-CoV-2 vaccine developed by China's Sinovac has a lower effectiveness rate than initially thought.

More Variants to Come

Additional, more contagious variants of SARS-CoV-2 are likely to crop up, the Financial Times says.

The analysis found that Archaic Age Caribbean populations had Central and northern South American-related ancestry, and no evidence of North American-related ancestry.

In PLOS this week: cancer predisposition syndromes among pediatric cancer patients, analysis of Plasmodium vivax population genomics in Panama, and more.

In PNAS this week: Andean and Amazonian population genetics, lipid metabolism changes in gastric cancer linked to ferroptosis avoidance, and more.

Brazil halts a late-stage clinical trial of a coronavirus vaccine following a report of an adverse reaction in a participant, the Financial Times reports.

The firm will partner with startup GeneproDx on thyroid cancer diagnostic development, while a separate agreement with Endpoint Health will entail CDx development for critical illness. 

The deal with GeneproDx will focus on thyroid cancer, while the agreement with Endpoint Health will focus on CDx development for critical illnesses.

In PLOS this week: gene expression in muscle stem cells, blood metabolomic study of diabetic retinopathy complications, and more.

Call for Open Science

A number of United Nations agencies push for scientific findings to be made accessible through open science.

Pages

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.